Just received some good news for our lab: Congratulations Matthias on your ERC Advanced Grant 2022 🎉🥂 isb_bonn Rheinische Friedrich-Wilhelms-Universität Bonn

Great to see the work of my first PhD student finally published in Science Advances, extending our data-based modeling framework to study a network of proliferating cell populations in chronic inflammation. DRFZ IEO_Bonn ImmunoSensation Hausdorff Center science.org/doi/10.1126/sc…

Excellent presentation by Gonzalo at the Single Domain Antibodies Meeting 2023 in Paris on his generic #CRISPR #CAR T cell platform! Important tool to improve #cellular #cancer #immunotherapies Rheinische Friedrich-Wilhelms-Universität Bonn⁩ ⁦ImmunoSensation⁩ ⁦MSSO Aachen | Bonn | Cologne | Düsseldorf⁩ ⁦IEO_GloddeLab⁩

Please read our latest article published in British Journal of Cancer on the characterization of #testiscancer related somatic-type malignancies on epigenetic and molecular level... Uniklinik Düsseldorf Heinrich-Heine-Universität Düsseldorf Malignant Germ Cell International Consortium European Association of Urology (EAU) DGU Uni Göttingen nature.com/articles/s4141…

Congratulations to Niklas Klümper from IEO_Bonn & Dept. of. Urology Uniklinik Bonn for this prestigious research award DGU Kongress. Happy to support & mentor. Perfect example for the success of #clinicianscientist programs DGU Rheinische Friedrich-Wilhelms-Universität Bonn BONFOR BMBF ACCENT

All true and indeed, we will not give up. We need #innovation for our (cancer) patients. MSSO Aachen | Bonn | Cologne | Düsseldorf is a nice example for a program supporting #cancer #research. Impressive young scientists & interdisciplinary spirit #CIOabcd. Thanks for funding Deutsche Krebshilfe

Combo or sequence in #mRCC - odd question? #NIVOSWITCH tested switch-maintenance in mRCC 👉 ORR IO/TKI: 20 vs. 52% 👉 PFS IO/TKI: 3.0 vs. 11.9 mo 👉 2y-OS 64 vs. 66% 👉 supports use of IO-combos Tom Powles Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Enrique Grande sciencedirect.com/science/articl…

Thrilled to have received the CSL Centenary Fellowship today at the Australian Academy of Health and Medical Sciences meeting! This would have never been possible without the support from The Zehn Lab #Hedricklab KalliesLab and everyone Doherty Institute Thank you all 🙏🏼 Ready to go to work 💪🏼🥼🧬 #TeamTpex

It is so amazing. What a game changer

Verkaufsausstellung zugunsten von LebensWert: Mit einer Vernissage startet morgen im #CIO der #Uniklinik #Köln eine Ausstellung mit Werken des Kölner Künstlers Rudolf Watzlawik. Der Erlös kommt dem Verein LebensWert für krebskranke Patienten zugute. uk-koeln.de/uniklinik-koel…

Thanks Viktor Grünwald for highlighting our work on the value of NECTIN4 status to predict EV response at a stellar symposium with Petros Grivas Enrique Grande joaquim bellmunt at ESMO - Eur. Oncology aacrjournals.org/clincancerres/… OncoAlert UroToday.com Clinical Cancer Research Predictive biomarkers are needed !

In three Phase III trials (mUC: IMvigor211, mRCC: IMmotion151, NSCLC: OAK) immunotherapy prolonged OS when baseline serum albumin was >35g/L -> Prediction of less immune fitness via simple albumin measurement?onlinelibrary.wiley.com/doi/10.1002/ct… OncoAlert Clinical & Translational Immunology Tobias Bald IEO_Bonn

Last Christmas… this would have been much more difficult to do. Thank you ⁦⁦Generate:Biomedicines⁩.

Great to see EV+PEM being approved for 1L mUC based on EV-302 Tom Powles!🎉To further improve outcomes precision medicine is needed. Great overview of future directions by Matt Galsky🎯NECTIN4 again discussed to predict EV outcomes OncoAlert UroToday.com link.springer.com/article/10.100…

Congrats to Emma Grace Bawden & Thomas Gebhardt to this amazing work on #melanoma #immunity. Fantastic collaboration within Bonn & Melbourne Research and Graduate School. Thanks to DFG public | @[email protected] University of Melbourne Rheinische Friedrich-Wilhelms-Universität Bonn

NECTIN4 amplification predicts response to Enfortumab vedotin in mUC! It occurs frequently across solid tumors (app. 25% of mUC)➡️potential tumor-agnostic biomarker for NECTIN4-targeting therapies! Happy to share our poster K17 ASCO #GU24! Markus Eckstein OncoAlert UroToday.com

Exciting study reveals correlation between Trop2 target expression and anti-Trop2 ADC SG response in TNBC! Journal of Clinical Oncology The ASCO Post Paolo Tarantino Membranous target gene expression crucial for ADC efficacy! ➡️ well-established for Her2, Nectin4, and Folr1 ! We need to consider the

Final results from #ASCENT in Journal of Clinical Oncology. SG demonstrates huge OS benefits in patients with triple negative #breast #cancer. Although benefit present in all subgroups, there is an incremental benefit dependent on TROP2 surface expression 🏄‍♂️! 👉 another piece of the puzzle‼️🎯

Congrats to the 4 lead investigators Chun-Pu, Pierre, Astrid and Georgi from my lab The Netherlands Cancer Institute Oncode Institute + collaborators, reporting today in Cancer Cell several genes whose inactivation generates fitter immune T cells for enhanced tumor killing. cell.com/cancer-cell/fu…

Proud to be the mentor of Niklas Klümper in UroAgeCare funded by @DFG_public. Now, the work on NECTIN4 amplifications predicting response to enfortumab vedotin in patients with mUC is published in Journal of Clinical Oncology! Underscores the importance of #clinician #scientist #programmes.